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Activation of the complement system results in
formation of membrane attack complexes (MACs),
pores that disrupt lipid bilayers and lyse bacteria
and other pathogens. Here, we present the crystal
structure of the first assembly intermediate, C5b6,
together with a cryo-electron microscopy recon-
struction of a soluble, regulated form of the pore,
sC5b9. Cleavage of C5 to C5b results in marked
conformational changes, distinct from those ob-
served in the homologous C3-to-C3b transition. C6
captures this conformation, which is preserved
in the larger sC5b9 assembly. Together with anti-
body labeling, these structures reveal that comple-
ment components associate through sideways
alignment of the central MAC-perforin (MACPF)
domains, resulting in a C5b6-C7-C8b-C8a-C9 arc.
Soluble regulatory proteins below the arc indicate
a potential dual mechanism in protection from
pore formation. These results provide a structural
framework for understanding MAC pore formation
and regulation, processes important for fighting
infections and preventing complement-mediated
tissue damage.
INTRODUCTION
Proteins of the terminal pathway of complement provide
immune protection by forming lytic pores, membrane attack
complexes (MACs), in membranes (Esser, 1994). Genetic defi-
ciencies of MAC components lead to recurrent infections (Botto
et al., 2009); however, unregulatedMAC formation causes tissue
damage (Morgan, 1999). Formation of the MAC is a sequential
process. Upon complement activation, C5 is cleaved into C5a200 Cell Reports 1, 200–207, March 29, 2012 ª2012 The Authorsand C5b by the C5 convertase. C6 then captures a labile bind-
ing site in C5b (half-life: 2 min) (Cooper and Mu¨ller-Eberhard,
1970), followed by C7 association that renders the complex
lipophilic (Preissner et al., 1985; Stewart et al., 1987). Binding
of heterotrimeric C8abg defines the initial membrane insertion
event, with C8b mediating attachment to the assembly
precursor (Brannen and Sodetz, 2007; Stewart et al., 1987)
and C8a penetrating the bilayer (Steckel et al., 1983). Inserted
C5b8 functions as a receptor for C9 and catalyzes its oligomer-
ization, leading to membrane perforation and target cell lysis
(Podack et al., 1982; Tschopp, 1984; Tschopp et al., 1985).
Off-target assembly of the MAC in solution leads to binding of
clusterin and vitronectin, yielding a soluble complex called
sC5b9 or sMAC. Dissociation of these chaperones by deter-
gents reconstitutes membrane binding (Bhakdi et al., 1979;
Podack and Mu¨ller-Eberhard, 1980). In addition, sC5b9 and
the lytic MAC share a neo-epitope present in C9 that is associ-
ated with pore formation (Mollnes et al., 1985), suggesting simi-
larities in how the soluble andmembrane-associated complexes
are assembled.
MAC proteins and the homologous perforin are proposed to
form b-barrel pores on the basis of the structural resemblance
between MAC-perforin (MACPF) domains and bacterial choles-
terol-dependent cytolysins (CDCs) (Hadders et al., 2007; Law
et al., 2010; Lovelace et al., 2011; Rosado et al., 2007; Rossjohn
et al., 1997; Shatursky et al., 1999; Slade et al., 2008). Modeling
and labeling of the perforin pore based on a cryo-EM reconstruc-
tion indicated, however, an inside-out arrangement of the per-
forin core relative to the proposed pore model for CDCs (Law
et al., 2010). Though a recent crystal structure of the heterotri-
meric C8abg suggested a CDC-like arrangement of the MAC
ring (Lovelace et al., 2011), it lacked the context of the larger
MAC assembly. To understand how complement proteins
come together to form a lytic pore important for immune
defense, we combined crystallographic analysis of C5b6 with
electron microscopy (EM) to determine the structure of the
sC5b9 complex.
RESULTS
Crystal Structure of C5b6
C5b6 was assembled in vitro, purified, and crystallized. Crystals
diffracted anisotropically to a resolution between 3.5 and 4.2 A˚,
and the structure was solved by molecular replacement (Table
S1). The final model, consisting of all 12 domains of C5b and
all 10 domains of C6, was refined to a final Rwork/Rfree of
25.6/27.0 and displayed good geometry (Figures 1A–1C, Fig-
ure S1A, and Table S1). Because of the limited resolution, we
restrict our discussion of the structure to the level of individual
domains.
C5 undergoesmarked domain rearrangements upon cleavage
into C5b and formation of the C5b6 complex. C5 consists of two
peptide chains, denoted b (residues [res.] 1–674) and a (res. 678–
1676), that form 13 domains (Fredslund et al., 2008) (Figure 1B).
Similar to the conversion of homologous C3 to C3b (Janssen
et al., 2006; Janssen et al., 2005), the domains of the a chain
undergo major relocations, while most of the b-chain forms
a stable ring-like structure (Figure 1E, Table S2, Movie S1).
Removal of the anaphylatoxin (ANA/C5a) domain results in
extensive movements of the macroglobulin (MG) 3, MG7,
MG8, and ‘‘complement C1r/C1s, Uegf, Bmp1’’ (CUB) domains
and the thioester-like domain (TED/C5d); C5 lacks the prototyp-
ical thioester present in this domain in other members of the C3/
a2-macroglobulin protein family. Although the concerted move-
ment of MG7 and CUB resembles that observed for the C3-C3b
transition, the position of the connected TED differs dramatically
(Figures 1D and 1E, Table S2). In C5b6, TED is positioned
halfway up the b-ring, in contrast to C3b, where TED lies at the
‘‘bottom’’ (Figures 1D and 1E). A requirement for this conforma-
tion to be caught and stabilized by C6may explain the short half-
life of the C6 binding site in C5b (Cooper and Mu¨ller-Eberhard,
1970). Without C6 binding, C5b will irreversibly decay to a state
incapable of binding C6 (Cooper and Mu¨ller-Eberhard, 1970).
The structure of C6 in the C5b6 complex reveals that its ten
domains can be divided into two functional parts. The first
consists of the six N-terminal domains and includes the ‘‘core’’
region common to all MACPF proteins in the MAC; these six
domains are thrombospondin (TSP) domain 1, TSP2, low-
density lipoprotein receptor class A domain (LDLRa), MACPF,
epidermal-growth factor (EGF) domain, and TSP3. The second,
C-terminal part consists of two complement-control-protein
(CCP) and two factor I/MAC (FIMAC) domains (Figures 1A, 1C,
and 1F). These regions are separated by a long flexible linker.
A comparison with free C6 (Aleshin et al., 2012) reveals that
whereas the N-terminal region is highly similar, the C-terminal
region has a strikingly different arrangement (Figures 1A
and 1F, Table S3) and forms the major interface with C5b.
The C5b-C6 interface buries ± 3100 A˚2 of solvent accessible
surface area. The core of C6 binds to the ‘‘bottom’’ of C5b, in
between MG1, MG4, and TED, to a highly conserved patch (Fig-
ure 2A). A second, major interface is formed by the linker and the
CCP1-2 domains of C6 that wrap around the TED domain of C5b
(Figure 2A). The CCP1 domain is wedged in between TED, CUB,
and MG2 of C5b, where it seems to stabilize the observed posi-
tion of TED (Figures 1 and 2). The importance of this interaction is
supported by data showing that the CCP domains are essentialfor C6 activity (DiScipio et al., 1999). The linker preceding CCP1
also makes extensive contacts with TED (Figures 2A and 2C),
where it interacts in part with a distinct b-hairpin that forms
a unique insertion in TED (Figures 2C, 2D and S1B–S1D). We
tested the importance of the linker region by mutating several
conserved residues, all showing a reduced activity in a hemolytic
assay (Figure 2B).
The observed association of C6 to C5b positions the MACPF
domain with its putative b-barrel forming transmembrane
segments (TMS) at the periphery of the complex (Figure 1A).
The two TMS regions in C5b6 (C6 res. 255–312 and res. 381–
438) adopt helical conformations loosely folded onto the central
curved four-stranded b sheet of the C6 MACPF; a similar
arrangement is observed in structures of free C6 (Aleshin et al.,
2012), C8 (Hadders et al., 2007; Lovelace et al., 2011; Slade
et al., 2008), perforin (Law et al., 2010), and CDCs (Rossjohn
et al., 1997). Importantly, we do not observe a structural rear-
rangement of these regions compared to free C6, suggesting
that binding to C5b is not the trigger for unfolding of these
segments. Thus, we interpret the MACPF fold of C6 in C5b6 as
a premembrane attack state, which is in agreement with the
soluble nature of C5b6.
Cryo-EM of the Soluble Regulated Pore, sC5b9
To understand how the MAC proteins arrange to form a pore, we
examined by EM sC5b9 purified from activated serum (Fig-
ure S2). Broadly, sC5b9 is a thin, square-shaped complex with
a single protrusion at one corner, as suggested by two-dimen-
sional (2D) images (Figure 3, Figures S2A–S2E). Three-dimen-
sional structures of both negatively stained and cryo-EM
sC5b9 (Figure S2F) further define two prominent features of
the square-like central region. The protrusion (Figure 3A, indi-
cated by a brown arrow) connects to the core at one corner of
an arc-shaped crescent, while large connected densities form
a butterfly arrangement below the arc (Figure 3A, indicated by
a gray surface).
Docking of the C5b6 crystal structure into the 24 A˚ cryo-EM
molecular envelope clearly defined the identity of the protrusion
asC5b6. Strikingly, the labile conformation of C5b trapped byC6
in the C5b6 crystal structure is preserved in the larger complex
(Figures 1A and 3E). The orientations of the C-terminal FIMAC
domains of C6 and the C345C domain of C5b, likely affected
by crystal packing, did not fit the density of the sC5b9 recon-
struction (Figures S1E–S1G). In addition, the C6 TSP1 domain,
thought to regulate assembly of MAC precursors (Aleshin
et al., 2012), was also out of density. Our map could accommo-
date these domains (Figure 3E, indicated by asterisks); however,
low resolution precluded modeling their orientations in the
sC5b9 reconstruction.
Next, we generated a model of multiple MAC proteins that
contain the conserved TSP-LDLRa-MACPF-EGF domain archi-
tecture (Figure S3) by duplicating the MACPF-MACPF orienta-
tion of C8ab (Lovelace et al., 2011). Five MAC proteins fit the
arc below the protrusion (Figure 3E). Labeling with a monoclonal
anti-C9 antibody, recognizing a neo-epitope present in both
sC5b9 and the lytic pore, identified C9 as the MAC protein in
the arc furthest from the C5b protrusion (Figures 3C–3E and
S4). Previous biochemical data showed that C9 binds to C8aCell Reports 1, 200–207, March 29, 2012 ª2012 The Authors 201
Figure 1. The Structure of C5b6
(A) A cartoon and surface representation of C5b6 in two orientations. C5b is colored in cyan, and C6 is colored by domain boundaries.
(B) A schematic representation of the domain architecture of C5b.
(C) A schematic representation of the domain architecture of C6.
(D) A cartoon representation of C5b (cyan) superimposed onto C5 (blue; PDB code 3CU7). C5a is colored red.
(E) A cartoon representation of C5b (cyan) superimposed onto C3b (purple; PDB code 2I07).
(F) A cartoon representation of C6 from the C5b-C6 complex (brown) superimposed onto free C6 (green; PDB code 3T5O), based on their MACPF domains.
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Figure 2. Interface of the C5b6 Complex
(A) The interface between C5b and C6 with the complex ‘‘spread’’ apart. C5b is cyan, with the C6 footprint colored according to the contacting C6 domains. C6 is
colored as in Figure 1, and the footprint of C5b is cyan.
(B) Hemolytic activity of C6 linker mutants expressed as a percentage relative to recombinant wild-type C6. Each sample was tested at six different concen-
trations, and standard errors were determined with the use of a nonlinear fitting program (GraFit 5.0).
(C) A close-up of the C5b-C6 interaction shows the extensive interface between TED and the C6 linker. Mutated residues tested in (B) are shown as spheres. The
unique b-hairpin of C5 (TED) that interacts with the linker is highlighted in red.
(D) Structure-based alignment of C5 and C3; the unique insertion in C5 is boxed.(Slade et al., 2006) and that C8b binds C5b7 (Brannen and
Sodetz, 2007; Stewart et al., 1987), indicating C8ba as the two
MAC components preceding C9. Independent docking of the
five-MAC model and C5b6 into the EM map superimposes the
core of C6 onto the first MAC position (Figure S3A), suggesting
that C6 is the first MAC protein and C7 is in the remaining
unoccupied position, the second position between C6 and
C8b. Models involving a six-MAC protein arc correlated less
well with the EM density (correlation coefficients of 0.88 and
0.84 for five- and six-membered arcs, respectively). It is note-
worthy that models involving the C6-C7-C8b-C8a-C9 arrange-
ment, in which the position of C6 was defined by docking
C5b6 as a rigid body, correlated 7% better with the map than
those ordered C7-C6-C8b-C8a-C9 as previously proposed
(Aleshin et al., 2012).
Density in the center of the arc accommodates the lipocalin
fold of C8g (Figure 3E, indicated as a solid gray surface),
a MAC component that is flexibly, but covalently, attached to
C8a (Lovelace et al., 2011; Slade et al., 2008) (Figure S3C).
C8g enhances lysis, but it is not essential (Parker and Sodetz,
2002) for MAC activity, and its orientation in sC5b9 suggests
a role in stabilizing the MACPF-MACPF interactions before
closure of the ring. Finally, density present at a ridge along
C5b (Figure 3E, indicated with a dashed orange line) couldaccount in part for the unmodeled CCP1-2 and FIMAC1-2
domains of C7, known to interact with the C345C domain of
C5b (Thai and Ogata, 2004).
Density of the butterfly-shaped region of the sC5b9 map can
be attributed to regulatory proteins, vitronectin and clusterin,
known to bind exposed lipophilic regions of MAC precursors.
This is supported by previous EM analysis of gold-labeled vitro-
nectin localizing oligomers to this region (Preissner et al., 1989).
Moreover, the location of regulatory proteins is consistent with
the positioning of predicted transmembrane segments below
the MACPFs in the arc and the interpretation that these
segments are either disordered or flapped out into their b-hairpin
conformation (Figure 4). The structural data, therefore, indicate
a potential dual mechanism in protection from pore formation:
the two ‘‘wings’’ of the butterfly-shaped regulatory region cap
the ends of the MAC arc and thereby block C9 oligomerization,
and they enwrap the lipophilic segments to prevent membrane
interaction.
DISCUSSION
Pore formation for MACPF-containing proteins involves
a dramatic conformational change in which helical bundles
transform into a membrane-spanning b-barrel. In contrast toCell Reports 1, 200–207, March 29, 2012 ª2012 The Authors 203
Figure 3. Cryo-EM Structure of sC5b9
(A) MAC components (brown surface) consist of an arc-shaped crescent with a single protrusion (brown arrow), while regulatory domains form a butterfly-like
structure (gray surface) below.
(B) Class averages of negatively stained sC5b9.
(C) Additional density present in the antiC9:sC5b9 averages identifies C9 in the complex (black arrow).
(D) Raw images of antiC9:sC5b9. Black arrow indicates antibody.
(E) Pseudoatomic model for MAC components consists of C5b6 (C5b, cyan; C6, blue), and C8 (C8a, dark gray; C8b, green; C8g, light gray solid surface) crystal
structures andmodels for C7 (orange) and C9 (purple). The dashed orange line indicates a ridge connecting the arc with C345C. Cyan and blue asterisks indicate
unmodeled density near C345C of C5b and CCP1 of C6, respectively.
Scale bars represent 160 A˚ (B–D).the current model for immune pore formation, which is based on
perforin (Law et al., 2010), our structural analysis of C5b6 and the
sC5b9 complex supports a model for the MAC that resembles
bacterial CDC pores (Figure 4). Docking of C5b6 into the
complex, the curvature of the arc, and density for C8g inside
the pore are all in concordance with the CDC orientation of
MACPF proteins in the membrane. Despite its similarity to
simpler bacterial pores, the complement-mediated immune
response has evolved complex assembly and regulatory mech-
anisms that are likely required to prevent host tissue damage yet
effectively clear pathogen infections. Our model suggests that
the ability of C6 to capture a labile binding site in C5b to form
an assembly competent state provides the first checkpoint in
MAC formation. Next, C7 binds the C5b6 complex, making
extensive contacts to C5b through its C-terminal CCP and
FIMAC domains, thereby aligning MACPF domains of C6 and
C7. Binding of C7 then drives rearrangement of the TMS regions,
making C5b7 lipophilic and creating the novel hybrid-binding site
for C8. Subsequent association of C8abg through alignment of
the C8b and C8a MACPF domains relocates C8g, which in the
soluble C8abg complex may serve to inhibit C9 association
before incorporation into the larger assembly. Finally, host regu-
latory proteins clusterin and vitronectin can prevent pore forma-
tion by blocking both hairpin insertion into the membrane and
oligomerisation of C9. Together, our data show how the MAC
is assembled and regulated in blood, providing a framework204 Cell Reports 1, 200–207, March 29, 2012 ª2012 The Authorsfor understanding the role of complement in microbial infection
and inflammatory disorders.
EXPERIMENTAL PROCEDURES
Purification of C5b6
C5b6 was isolated from amixture of purified human C5 and C6 in which the C5
was activated by addition of a mixture of cobra venom factor (CVF), factor B,
and factor D in the presence of 0.5 mM MgCl2. C5 and C6 were purified from
pooled normal human serum as previously described (Kolb et al., 1982; Tack
et al., 1980). The formed C5b6 complex was separated from the other compo-
nents by ion exchange chromatography over a Mono Q column (GE Health-
care) and subsequently by gel filtration over BioGel A0.5 m (BioRad). Fractions
were pooled on the basis of C5b6 functional activity (Rawal and Pangburn,
2000), concentrated to 0.7 mg/ml and dialyzed against 10 mM HEPES (pH
7.2), 120 mM NaCl, and 0.02% w/v NaN3.
Crystallization and Data Collection
The C5b6 complex was crystallized by vapor diffusion in hanging drops con-
sisting of 2.5 ml protein (0.7 mg/ml) mixed with 0.5 ml 1M HEPES-NaOH (pH
7.8). Drops were equilibrated at 18C over 300 ml reservoir solution consisting
of 0.1M HEPES-NaOH (pH 7.8) and 250 mM NaCl. Crystals grew to maximum
dimensions of 8003 803 20 mm in3 weeks and were cryoprotected by brief
incubation in reservoir solution supplemented with 30% (v/v) ethylene glycol,
followed by flash freezing in liquid N2. A complete data set was collected at
ESRF beamline ID29 in seven wedges of 15 that were collected along the
length of the crystal through the use of 1 oscillations. The diffraction data
were integrated and scaled by XDS (Kabsch, 2010) and Aimless (Collaborative
Computational Project, Number 4, 1994). The crystals belong to space group
Figure 4. A Model for MAC Formation
The complement terminal pathway is initiated by the cleavage of C5 to C5b. C6 traps a labile conformation of the C5b TED domain to formC5b6, a platform for the
stepwise assembly of components C7, C8, and C9. Regulatory proteins in the plasma block MAC assembly in solution by binding exposed hydrophobic regions
and sterically inhibit C9 oligomerization. Binding of C5b8 to membranes recruits multiple C9 molecules whose MACPF domains arrange to form a b-barrel pore
similar to that of CDCs.I212121, have unit-cell parameters of a = 154.2, b = 230.8, and c = 270.0 A˚, and
contain one complex of C5b6 in the asymmetric unit (solvent content: 72%).
The diffraction data were strongly anisotropic, extending to 4.2 A˚ resolution in
the direction of a*, 3.8 A˚ in the direction of b*, and 3.5 A˚ in the direction of c*.
These resolution limits were determined by applying a cutoff based on either
a mean intensity correlation coefficient of half-data sets > 0.5 or F/sF = 3.
Both methods gave the same value for resolution cutoffs.
Structure Determination and Refinement
The structure of C5b6 was solved bymolecular replacement through the use of
PHASER (McCoy et al., 2007). A solution could be found by using the known
structures of C5 (PDB code 3CU7; Fredslund et al., 2008) and C6 (PDB code
3T5O; Aleshin et al., 2012), while prior to the publication of the C6 structure
amodelofC6hadbeengeneratedstarting from fragmentsof homologousstruc-
tures. TheC5 coordinates were separated into TED (res. 986–1305), the b-chain
(res. 20–607), and the MG7 (res. 822–931), MG8 (res. 1374–1512), CUB (res.
932–985, 1308–1368), and C345C domains (res. 1530-1676), while the C6
coordinates were separated into the core (res. 22–629), the CCP domains
(res. 641–765), and the FIMAC domains (res. 771–934). The model was
completed by iterative model building in Coot (Emsley and Cowtan, 2004) and
refinement in Phenix (Afonine et al., 2010) and autoBuster (Blanc et al., 2004).
Although the data set used for refinement was strongly anisotropic, (4.2–3.5 A˚;
see above), we used all data up to 3.5 A˚ for refinement, as anisotropic truncation
did not improve refinement statistics or map quality. Initial refinement runswere
heavily restrained and involved the use of both secondary structure and Rama-
chandran restraints as implemented by Phenix (Afonine et al., 2010). In later
stages of refinement, themodel fromPhenixwas used to generate LSSR-based
target restraints as implemented by autoBuster (Blanc et al., 2004). The refine-
ment strategy further included individual positional and B factor refinement
and TLS refinement using 11 TLS groups. The model was refined to an Rfree
of 27.0%anddisplays goodgeometry,with88.9%of the residues in the allowed
and 0.5% of the residues in the disallowed regions of the Ramachandran plot.
Expression and Purification of C6
C6 constructs were expressed as His6-tagged N-terminal fusions in transiently
transfected suspension cultures of N-acetylglucoaminyltransferase-I-deficientHEK293E cells (Utrecht-ProteinExpress). Medium was harvested six days
after transfection, then concentrated 10-fold and buffer-exchanged with
the use of a 30 kDa cutoff filter (Quixstand hollow fiber; GE Healthcare). The
proteins were purified by Ni-SepharoseTM 6 Fast Flow (GE Healthcare) and
size exclusion chromatography with the use of a SuperdexTM 200 10/300
column equilibrated in 20 mMHEPES-NaOH (pH 7.4) and 150 mMNaCl. Frac-
tions containing the C6 construct were pooled, concentrated, and flash frozen
in liquid N2. All proteins were stored at 80C until use.
Hemolytic Assay
C6 was assayed for hemolytic activity with the use of antibody-sensitized
sheep erythrocytes (EA) and C6-depleted human serum (Complement Tech-
nology), as described previously (Rawal and Pangburn, 2000). Hemolytic titers
(ng C6 required for lyse of 50% of the EA) were determined, and the activities
were normalized to recombinant wild-type C6. Each sample was tested at six
different concentrations (n = 6). Standard errors were calculated with
a nonlinear fitting program (GraFit 5.0, Erithacus software).
Purification of sC5b9
Blood was collected from healthy volunteers and allowed to clot, and serum
was separated within 1 hr of collection. To activate complement by both clas-
sical and alternative routes, zymosan (10 mg/ml; Sigma) and heat-aggregated
human IgG (1mg/ml; made in house) were added to the serum and incubated
overnight at 37C. Particulates were removed by centrifugation and filtration
(0.2 mm). Serumwas then applied on an affinity column (HiTrap; GEHealthcare)
to which 40 mg mouse anti-human C8 monoclonal antibody E2 (generated in
house) was coupled. Protein was eluted in 0.1 M glycine (pH 2.5) and neutral-
ized by collection into 0.5 M Tris buffer (pH 8.0). sC5b9 containing fractions
were pooled, concentrated, and applied to a preparative scale gel filtration
column (Superdex-200 matrix in a XK16/70 column; GE Healthcare) equili-
brated in PBS (137 mM NaCl, 10 mM phosphate, 2.7 mM KCl [pH 7.4]).
Immediately before analysis, sC5b9 was further purified by two successive
purifications on a Superose 6 PC 3.2/30 gel filtration column in a buffer con-
taining 150 mM NaCl, 50 mM Tris (pH 7.5), 1 mM CaCl2, and 1 mM MgCl2.
Antibody-labeled sC5b9 complexes were generated by incubating 5 mg of
monoclonal antibody, aE11 (Hycult Biotech), with 7.5 mg sC5b9 for 20 min atCell Reports 1, 200–207, March 29, 2012 ª2012 The Authors 205
room temperature. Excess antibodywas removed by gel filtration as described
above.
Negative Stain Electron Microscopy
Immediately after gel filtration, a volume of 2.5 ml of sC5b9 (16 mg/ml) or anti-
body-labeled sC5b-9 (9 mg/ml), were applied to glow-discharged carbon-
coated copper grids. Grids were negatively stained with 0.75% uranyl formate.
Images were taken under low-dose conditions (10 e/A˚2 per exposure) at
a nominal magnification of 72,500 on a JEOL JEM-1230 operated at 100 kV.
Images were recorded on a 4k 3 4k TemCam-F416 camera (TVIPS) and
2.28 A˚/pixel. 11330 sC5b9 and 1104 immune-labeled windowed particles
were each subjected to reference-free alignment with the use of EMAN2
(Tang et al., 2007) and classified into 149 and 31 classes, respectively. The
standard EMAN2 initial-model-generation program (e2initialmodel.py) was
used to obtain an initial template for refinement. With the use of this method-
ology, several models were constructed from a series of randomly generated
Gaussian blobs, masked according to the sC5b9 particle diameter, and used
to initiate the angular assignment of reference-free-generated 2D class aver-
ages. The resulting models were ranked on the basis of the agreement of
the projection with the class average. The top choice was used as template
for the refinement of negatively stained sC5b9 single particles with the use
of EMAN2. Handedness of the map was determined on the basis of an 8%
difference in correlation coefficient used for measuring the agreement of the
C5b6 crystal structure with the reconstruction.
Cryo-Electron Microscopy
The identical preparation used in the negative stain EM experiments described
above was also subjected to analysis by cryo-EM. Aliquots (4 ml) of purified
sC5b9 (0.1 mg/ml) were applied to glow-discharged holey carbon grids
(QUANTIFOIL R 1.2/1.3) and vitrified in liquid ethane with an FEI Vitrobot.
Images were acquired on a JEM-200FS FEG electron microscope (JEOL)
operating at 200kV, equipped with an in-column energy filter (OMEGA).
Images were recorded with a defocus range of 3.0 to 6.0 microns underfo-
cus and at a magnification of 54,400 on a 4k3 4k ULTRASCAN 4000 SP CCD
camera, corresponding to 2.76 A˚/pixel. A total of 18,983 individual sC5b9
particles were windowed with e2boxer (EMAN2), corrected for the contrast
transfer function (CTF) with Bsoft (Heymann and Belnap, 2007), and low-
pass filtered to 11 A˚. The sC5b9 negative stain reconstruction served as a
reference for the refinement of cryo-EM data through the use of projection-
matching algorithms in Xmipp (Scheres et al., 2008). All fitting and rigid-body
refinement of pseudo-atomic models into the cryo-EM envelope were per-
formed in Chimera (Pettersen et al., 2004). Figures were generated withPymol
(PyMOL Molecular Graphics System, version 1.3, Schro¨dinger).
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